Literature DB >> 11283929

Prospective study of correlations between biopsy-detected high grade prostatic intraepithelial neoplasia, serum prostate specific antigen concentration, and race.

J E Fowler1, S A Bigler, C Lynch, S S Wilson, P B Farabaugh.   

Abstract

BACKGROUND: High grade prostatic intraepithelial neoplasia (HGPIN), a premalignant lesion of the prostate gland, is more common in black men than in white men. The influence of HGPIN on the serum prostate specific antigen (PSA) concentration is controversial, and correlations between HGPIN and PSA in black men and white men have not been investigated.
METHODS: Between January 1992 and December 1998, 411 black men and 639 white men with suspected prostate carcinoma underwent an initial benign prostate biopsy at a single medical center. The presence or absence of HGPIN in the biopsy specimens was determined by one uropathologist.
RESULTS: HGPIN was identified in 8.9% of the specimens. When stratified by PSA concentration (< 4.0 ng/mL, 4.0-9.9 ng/mL, and > or = 10.0 ng/mL), HGPIN was associated with an increased PSA concentration only among men with PSA concentrations < 4.0 ng/mL (P = 0.01). The prevalence of HGPIN in the black and white patients was 13.4% and 5.9%, respectively (P < 0.0001), and was significantly greater in black men than in white men with PSA concentrations < 4.0 ng/mL (P = 0.002). Among the patients with PSA concentrations < 4.0 ng/mL, black race was an independent predictor of an increased PSA concentration when adjusted for patient age, prostate volume, and the presence or absence of HGPIN (P = 0.03).
CONCLUSIONS: HGPIN is more common in black men than in white men and may produce an increase in the PSA concentration. However, racial differences in the prevalence of HGPIN may not contribute to racial differences in PSA concentrations among men with no clinical or histologic evidence of carcinoma. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11283929     DOI: 10.1002/1097-0142(20010401)91:7<1291::aid-cncr1131>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  High-grade prostatic intraepithelial neoplasia.

Authors:  David G Bostwick; Lina Liu; Michael K Brawer; Junqi Qian
Journal:  Rev Urol       Date:  2004

2.  Prostatic intraepithelial neoplasia: an overview.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2005

3.  Race Differences in Telomere Length in Benign Prostate Biopsies and Subsequent Risk of Prostate Cancer.

Authors:  Benjamin A Rybicki; Sudha M Sadasivan; Yalei Chen; Ian Loveless; Nilesh S Gupta; Dhananjay A Chitale; Sean R Williamson; Andrew G Rundle; Deliang L Tang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-05-04       Impact factor: 4.090

Review 4.  Precursor lesions to prostatic adenocarcinoma.

Authors:  Jonathan I Epstein
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

5.  High grade prostate intraepithelial neoplasia (PIN) is a PSA-independent risk factor for prostate cancer in African American men: results from a pilot study.

Authors:  Ganna Chornokur; Gang Han; Richard Tanner; Hui-Yi Lin; B Lee Green; Julio Pow-Sang; Catherine M Phelan
Journal:  Cancer Lett       Date:  2012-12-23       Impact factor: 8.679

Review 6.  Importance of Estrogenic Signaling and Its Mediated Receptors in Prostate Cancer.

Authors:  Kin-Mang Lau; Ka-Fai To
Journal:  Int J Mol Sci       Date:  2016-08-31       Impact factor: 5.923

7.  Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention.

Authors:  Nagi Kumar; Ganna Chornokur
Journal:  Transl Med (Sunnyvale)       Date:  2012-12-31

8.  Safety and tolerability of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN).

Authors:  Mikhail Paltsev; Vsevolod Kiselev; Ekaterina Muyzhnek; Vadim Drukh; Igor Kuznetsov; Olga Pchelintseva
Journal:  EPMA J       Date:  2014-10-08       Impact factor: 6.543

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.